Science & Enterprise subscription

Follow us on Twitter

  • Genny Cream for me, if I were there https://t.co/BQcWbr7yLh
    about 2 hours ago
  • As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project… https://t.co/pyDX0IWnCs
    about 7 hours ago
  • New post on Science and Enterprise: Infographic – Public Money Funds Covid-19 Vaccines https://t.co/1D2XLhUi4Z #Science #Business
    about 7 hours ago
  • Excellent analysis. Real example: a colleague I hired at Science mag is leaving her job to get a grad degree in IT. https://t.co/c0qnYW025H
    about 10 hours ago
  • Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immun… https://t.co/4lK4qD5p6m
    about 1 day ago

Please share Science & Enterprise

Infographic – Public Money Funds Covid-19 Vaccines

Chart: Covid-19 vaccine funding

As the race to produce and distribute Covid-19 vaccines intensifies, financing of this global public health project is starting to emerge. . . . → Read More: Infographic – Public Money Funds Covid-19 Vaccines

Biotechs Partner on Gene-Edited Cancer Cell Therapies

Natural killer cell

Two biotechnology companies are collaborating on using the gene editing technique Crispr to create engineered immune-system cells to treat cancer. . . . → Read More: Biotechs Partner on Gene-Edited Cancer Cell Therapies

AI Gene Therapy Platform Gains $100M in Early Funds

Adeno-associated virus

A company using machine learning to create engineered viruses to deliver gene therapies is raising $100 million in its first venture funding round. . . . → Read More: AI Gene Therapy Platform Gains $100M in Early Funds

Cell Therapy Mfring Company Raises $82M in Venture Funds

T-cells and cancer cells

A company developing an automated yet personalized manufacturing platform for cell therapies is raising $82 million in its second venture funding round. . . . → Read More: Cell Therapy Mfring Company Raises $82M in Venture Funds

Antibody Clears Covid-19 Variants, Enters Trial

SARS-Cov-2 virus

A synthetic antibody is shown in lab tests to neutralize variants of the SARS-CoV-2 virus, and will be added to an ongoing clinical trial of Covid-19 therapies. . . . → Read More: Antibody Clears Covid-19 Variants, Enters Trial

Moderna Supplying 500M Vaccine Doses to Covax

Vaccine delivery to Philippines

Moderna Inc. is providing up to 500 million doses of its Covid-19 vaccine to the Covax Facility, an international project distributing vaccines to low-income countries. . . . → Read More: Moderna Supplying 500M Vaccine Doses to Covax

Trial Shows Malaria Vaccine Protects Young Children

Malaria clinic in Cameroon

Results from a clinical trial in Burkina Faso show a high efficacy rate for a candidate vaccine to protect young children against malaria infections. . . . → Read More: Trial Shows Malaria Vaccine Protects Young Children

Biomanufacturing Materials Company Issues $500M IPO

Wall Street sign

Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO

Trials Adding Covid-19 Hospital, Out-Patient Therapies

SARS-CoV-2 particle

National Institutes of Health is adding a new treatment to a clinical trial for Covid-19 patients hospitalized with severe respiratory failure. . . . → Read More: Trials Adding Covid-19 Hospital, Out-Patient Therapies

Microbiome Health Company Raises $40M in Early Funds

Gut microbes illustration

A developer of therapies and health products addressing microbes inhabiting the human body is raising $40 million in its first venture funding round. . . . → Read More: Microbiome Health Company Raises $40M in Early Funds